Company: MDCXW
Filing Date: 2025-11-19
Form Type: S-1
Source: 0001062993-25-016962
Chunk: 151

Company: Medicus Pharma Ltd.
Filing Date: 2025-11-19
Form: S-1
Chunk 151
---
 Congressional Task Force on Down Syndrome.

Ms. Rodgers received her Bachelor of Administration, Pre-Law, from Pensacola Christian College and her Executive Masters in Business Administration (EMBA) from Foster School of Business at the University of Washington.

Ajay Raju, Director

Ajay Raju has served as a member of our board of directors since July 2025.

<div align='center'>107</div>

Mr. Raju is a law firm leader who is highly involved in the civic interests of his community. His experience includes representation of clients in the structured finance and real estate capital markets sectors, guiding clients through mergers, acquisitions, divestitures, joint ventures and cross-border strategic transactions.

Mr. Raju currently serves as Chairman and CEO of Raju LLP (2021 to present), Co-Founder and Director of Avstera Therapeutics Corp. (2022 to present), Chairman of Indigo Global (2014 to present) and Managing General Partner at 215 Capital (2016 to present). Mr. Raju is also the Co-Founder and Chairman of The Germination Project (2014 to present), Founder and Chairman of THE ARK INSTITUTE (2021 to present) and Co-Founder and Chairman of The Philadelphia Citizen (2014 to present). Mr. Raju previously served as Chairman and CEO of Dilworth Paxson LLP (2014 to 2021) and as Managing Partner of Reed Smith's Philadelphia office (2003 to 2014), where he was a member of the firm's global executive committee.

Mr. Raju also sits on a number of civic boards, including the Philadelphia Museum of Art, the Greater Philadelphia Chamber of Commerce, the Zicklin Center at Wharton, the President's Council at Temple University and the Research Council at Penn Medicine.

Mr. Raju received his Bachelor of Arts and Juris Doctor degrees from Temple University.

Patrick J. Mahaffy, Director

Patrick J. Mahaffy has served as a member of our board of directors since August 2025.

Mr. Mahaffy is a biopharmaceutical executive with a track record of serial value creation in the field of oncology-focused drug development and commercialization in the US and Europe. He has successfully led multiple companies as President, CEO and Board Chair and served on the boards of several high-growth biotechnology companies and he brings strategic vision and insightful perspective on commercial development, marketing, portfolio strategy and operational and management expertise specific to novel oncology therapeutics, as well as targeted